Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$1.01 +0.01 (+1.00%)
As of 10:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VRAX vs. UPXI, EQ, NKGN, PRPH, ME, IBIO, SYBX, MRKR, NXTC, and AYTU

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Upexi (UPXI), Equillium (EQ), NKGen Biotech (NKGN), ProPhase Labs (PRPH), 23andMe (ME), iBio (IBIO), Synlogic (SYBX), Marker Therapeutics (MRKR), NextCure (NXTC), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs.

Virax Biolabs Group (NASDAQ:VRAX) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.

Virax Biolabs Group has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500.

In the previous week, Upexi had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Upexi and 0 mentions for Virax Biolabs Group. Upexi's average media sentiment score of 0.34 beat Virax Biolabs Group's score of 0.00 indicating that Upexi is being referred to more favorably in the news media.

Company Overall Sentiment
Virax Biolabs Group Neutral
Upexi Neutral

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 31.6% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Virax Biolabs Group has higher earnings, but lower revenue than Upexi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$84.87K38.47-$6.73MN/AN/A
Upexi$16.56M1.04-$23.66MN/AN/A

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Upexi N/A N/A N/A

Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 197.03%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Virax Biolabs Group is more favorable than Upexi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Upexi
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Upexi received 2 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. However, 100.00% of users gave Virax Biolabs Group an outperform vote while only 42.86% of users gave Upexi an outperform vote.

CompanyUnderperformOutperform
Virax Biolabs GroupOutperform Votes
1
100.00%
Underperform Votes
No Votes
UpexiOutperform Votes
3
42.86%
Underperform Votes
4
57.14%

Summary

Virax Biolabs Group beats Upexi on 9 of the 13 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$3.27M$2.59B$5.31B$8.28B
Dividend YieldN/A0.73%5.20%4.10%
P/E RatioN/A7.4026.7319.58
Price / Sales38.4735.27387.44119.65
Price / CashN/A15.7538.2534.62
Price / Book0.515.426.744.47
Net Income-$6.73M-$65.73M$3.23B$248.22M
7 Day Performance-6.48%-0.82%-0.05%-1.32%
1 Month Performance-0.98%-0.04%8.51%10.73%
1 Year Performance21.25%-15.96%18.25%8.40%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
2.904 of 5 stars
$1.01
+1.0%
$3.00
+197.0%
+18.7%$3.27M$84,872.000.005
UPXI
Upexi
0.7259 of 5 stars
$9.64
-5.4%
N/A+45.1%$13.75M$18.63M0.00130News Coverage
Earnings Report
EQ
Equillium
2.6089 of 5 stars
$0.38
+2.7%
$3.00
+681.3%
-72.3%$13.72M$41.10M-2.7440Gap Down
NKGN
NKGen Biotech
N/A$0.30
-14.2%
N/A-85.4%$13.48M$80,000.00-0.06N/APositive News
Gap Up
PRPH
ProPhase Labs
1.8266 of 5 stars
$0.32
-17.2%
N/A-94.1%$13.43M$6.77M-0.25130Earnings Report
Gap Down
ME
23andMe
N/A$0.50
-35.3%
N/A-95.2%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
IBIO
iBio
1.1488 of 5 stars
$0.80
0.0%
$4.30
+438.0%
-64.4%$13.20M$375,000.000.00100
SYBX
Synlogic
N/A$1.10
+1.9%
N/A-30.4%$12.87M$8,000.00-0.2680Upcoming Earnings
MRKR
Marker Therapeutics
4.0913 of 5 stars
$1.13
+1.8%
$13.17
+1,065.2%
-71.3%$12.79M$6.59M-0.8560Positive News
NXTC
NextCure
3.9414 of 5 stars
$0.45
+2.7%
$3.50
+677.8%
-69.3%$12.62MN/A-0.2290Positive News
Gap Down
AYTU
Aytu BioPharma
1.572 of 5 stars
$2.00
-6.1%
N/A-35.3%$12.34M$77.23M-1.38160High Trading Volume

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners